research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-02 and is reviewed periodically as new material appears.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
The causes are many and can be divided into conditions that have either true or perceived muscle weakness. True muscle weakness is a primary symptom of a variety of skeletal muscle diseases, including muscular dystrophy and inflammatory myopathy. It occurs in neuromuscular diseases, such as myasthenia gravis. Perceived muscle weakness occurs in diseases such as sleep disorders, and depression.
A replica of the San Juan Bautista was reconstructed in 1993 on the basis of the records of the House of Date. Although its blueprints have not been found, the ship's dimensions were recorded properly, permitting a speculative reconstitution. The ship was put on display in the Miyagi Sant Juan Bautista Museum in Ishinomaki, in northern Japan, close to the location where she was originally built. The replica survived the 2011 Tōhoku earthquake and tsunami with some damage, and there were hopes in 2011 of using the ship as a symbol of the town's reconstruction. In November 2013 the repaired San Juan Bautista was rededicated. Assistance had come from Western Forest Products, a British Columbia lumber company, who supplied the massive Douglas fir and cedar logs to create masts that had been damaged in the tsunami. However, the replica ship was deemed to be unsafe to the public due to structural damage from floodwater and other factors, and the Miyagi prefectural government decided to demolish the ship rather than to continue repairing it. Dismantling began in November 2021. The government built a new ship in its place, using fibre-reinforced plastic and reducing the size to one quarter of the original. The new, smaller ship was revealed to the public in October 2024.
In January 2011, the FDA asked manufacturers of prescription combination products containing paracetamol to limit its amount to no more than 325 mg per tablet or capsule and began requiring manufacturers to update the labels of all prescription combination paracetamol products to warn of the potential risk of severe liver damage. Manufacturers had three years to limit the amount of paracetamol in their prescription drug products to 325 mg per dosage unit. In November 2011, the Medicines and Healthcare products Regulatory Agency revised UK dosing of liquid paracetamol for children. In September 2013, "Use Only as Directed", an episode of the radio program This American Life highlighted deaths from paracetamol overdose. This report was followed by two reports by ProPublica alleging that the "FDA has long been aware of studies showing the risks of acetaminophen. So has the maker of Tylenol, McNeil Consumer Healthcare, a division of Johnson & Johnson" and "McNeil, the maker of Tylenol, ... has repeatedly opposed safety warnings, dosage restrictions and other measures meant to safeguard users of the drug." In September 2025, US President Donald Trump and HHS Secretary Robert F. Kennedy Jr. claimed that Tylenol may cause autism and urged pregnant women to avoid it; whereas medical experts, major health organizations, and international studies strongly dispute any causal link, emphasizing that the drug remains safe for treating pain and fever in pregnancy.
Sources: en.wikipedia.org
== Premise == One decade after most members of the Justice Society of America (JSA) are killed in battle against the Injustice Society of America (ISA), Courtney Whitmore, a high school student who moved to Blue Valley, discovers the Cosmic Staff of Starman and learns that her stepfather Pat Dugan used to be his sidekick. After encountering the remnants of the ISA which now include the mysterious Dragon King and his daughter Cindy Burman, Courtney becomes the inspiration for a whole new generation of superheroes and recruits Yolanda Montez, Rick Tyler, and Beth Chapel. In the second season, Stargirl and the JSA contend with the re-emergence of former ISA member Shade and a mysterious entity known as Eclipso, who works with Cindy to create a new ISA called Injustice Unlimited. When Eclipso breaks free from Cindy's control, the JSA works to stop him and finds new allies in Jennie-Lynn Scott, Jakeem Williams, Thunderbolt, a rescued Charles McNider, a revived Starman, and former ISA members Solomon Grundy, Sportsmaster, and Tigress. In the third and final season, the heroes and villains living in Blue Valley become embroiled in a murder mystery after former ISA member Steven Sharpe is found dead, while someone has been spying on them with cameras placed all over town. It turns out that a reconstituted Icicle was responsible as he is in league with the JSA's old enemy Ultra-Humanite and a surviving Dragon King.
When it was known as Boston Chicken, restaurants specialized in rotisserie chicken and a variety of side dishes, but in February 1995, the chain expanded its menu to include turkey, meatloaf, and ham and changed the name to Boston Market in the fall of 1995 to reflect this. The corporate name remained Boston Chicken, Inc. until 1997, when the new name became popular and the corporate name was changed to Boston Market Corporation. In 1995, Boston Chicken created the Einstein Bros. Bagels chain of bakery cafés, after acquiring several smaller chains of bagel-centric bakeries. In 1996, the chain launched "Boston Carver Sandwiches", which featured chicken, turkey, ham, and meatloaf; in 1997, due to the success of the sandwich line, "Extreme Carver" sandwiches, filled with larger portions of meat and cheese, were launched. The company raised a lot of debt to finance its expansion. The rapid expansion allowed the company to create a steady stream of revenue from one-time development fees and increasing royalties, but also raised interest rates on its development loans. In 1998, the company filed for Chapter 11 bankruptcy. Since April 1999, a selection of Boston Market-branded items have been available in many supermarkets across the United States. Boston Market was purchased by McDonald's Corporation in May 2000, primarily for its real estate holdings. McDonald's found the brand serviceable, and continued to operate and expand Boston Market. In the early 2000s, Boston Market operated two locations in Toronto, Ontario.
Steam power was resurrected in the 1950s with a nuclear-powered steam turbine driving a generator. By eliminating the need for atmospheric oxygen, the time that a submarine could remain submerged was limited only by its food stores, as breathing air was recycled and fresh water distilled from seawater. More importantly, a nuclear submarine has unlimited range at top speed. This allows it to travel from its operating base to the combat zone in a much shorter time and makes it a far more difficult target for most anti-submarine weapons. Nuclear-powered submarines have a relatively small battery and diesel engine/generator powerplant for emergency use if the reactors must be shut down. Nuclear power is now used in all large submarines, but due to the high cost and large size of nuclear reactors, smaller submarines still use diesel–electric propulsion. The ratio of larger to smaller submarines depends on strategic needs. The US Navy, French Navy, and the British Royal Navy operate only nuclear submarines, which is explained by the need for distant operations. Other major operators rely on a mix of nuclear submarines for strategic purposes and diesel–electric submarines for defense. Most fleets have no nuclear submarines, due to the limited availability of nuclear power and submarine technology. Diesel–electric submarines have a stealth advantage over their nuclear counterparts. Nuclear submarines generate noise from coolant pumps and turbo-machinery needed to operate the reactor, even at low power levels.
Sources: en.wikipedia.org
1973 ) tax lawyer, investigative journalist and commentator, researches and writes on issues of tax law and tax policy; worked as tax lawyer at international law firm Clifford Chance, becoming its UK head of tax ; was listed as one of the 50 most influential people in the world of tax policy and business by International Tax Review, and as one of the 100 most influential people in the world of private wealth by Spear's; was named the UK's leading accountancy influencer on social media by the Institute of Chartered Accountants in England and Wales; served on the National Constitutional Committee of the Labour Party, its senior disciplinary body; advises policymakers in five political parties and was member of the Scottish Government's Tax Advisory Group. Robert Peston (born 1960), BBC news business correspondent; author of Who Runs Britain? How the Super-Rich are Changing our Lives; son of Maurice Peston, Baron Peston (1931–2016), an economist and Labour life peer who had worked on the Lords Constitution Committee and on committee reviewing the BBC Charter and was chairman of the Pools Panel.
== History == In the early 1940s clinicians used extracts of growth factors and cytokines for healing. The term 'platelet-rich plasma' was first used in 1954 by Kingsley and in the 1960s the first PRP blood banks were established, becoming popular by the 1970s. In the 1970s PRP was used in hematology, originally for transfusions to treat thrombocytopenia. Ten years later it was used for maxillofacial surgeries. PRP was first used in Italy in 1987 in an open heart surgery procedure. In 2006 PRP was starting to be considered of potential use for both androgenic alopecia and alopecia areata.
The water absorption of aluminium and palladium becomes an unacceptable source of outgassing, and even the adsorptivity of hard metals such as stainless steel or titanium must be considered. Some oils and greases will boil off in extreme vacuums. The permeability of the metallic chamber walls may have to be considered, and the grain direction of the metallic flanges should be parallel to the flange face. The lowest pressures currently achievable in laboratory are about 1×10−13 torrs (13 pPa). However, pressures as low as 5×10−17 torrs (6.7 fPa) have been indirectly measured in a 4 K (−269.15 °C; −452.47 °F) cryogenic vacuum system. This corresponds to ≈100 particles/cm3.
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.